|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.
|
26708059 |
2016 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To measure ABCB1 function in tumors, we performed PET experiments using both [<sup>18</sup>F]AVT-011 and [<sup>18</sup>F]FDG in mice bearing orthotopic breast tumors (n = 7-10/group) expressing clinically relevant levels of ABCB1.
|
31729540 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this pilot study, MDR1 expression in primary breast tumors was inversely related with the efficacy of first-line chemotherapy, and high expression level was a significant predictor of poor prognosis for patients with advanced disease.
|
12576456 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression level of MDR1 and MRP1 were significantly higher in breast tumors than normal breast tissues.
|
23481629 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Reduced ABCB1 protein levels in breast tumors was associated with triple-negative subtype (adjusted odds ratio [OR<sub>adj</sub>] =0.24; 95% confidence interval [CI] =0.13-0.45), lymph node status < pN2 (OR<sub>adj</sub> =0.27; 95% CI =0.10-0.71), tumor size >2 cm (OR<sub>adj</sub> =0.55; 95% CI =0.32-0.93), and hypertensive status (OR<sub>adj</sub> =0.42; 95% CI =0.24-0.73), and it was significantly associated with shorter disease-free survival, either for all breast cancer patients (<i>p</i> log-rank =0.012; hazard ratio [HR] =3.46; 95% CI =1.21-9.91) or for those with triple-negative tumors (<i>p</i> log-rank =0.007; HR =11.41; 95% CI =1.29-100.67).
|
28670140 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, the mechanism of 99mTc-sestamibi uptake by nine human breast tumor cell lines was analyzed as a function of P-glycoprotein (PgP) expression.
|
8667063 |
1996 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Detectable levels of mdr1 mRNA was observed in 25 out of 49 breast tumours, with up to a 100-fold range in expression.
|
1970934 |
1990 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, evaluation of mdr1-RNA seemed to be of little interest in primary breast tumors.
|
8251651 |
1993 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taken together, our data indicate that breast tumors with alveolar structures possess resistance to NAC, which is not related to high expression of MDR genes, whereas chemoresistance of tumors with trabecular structures can depend on the expression level of ABCB1.
|
24736530 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An important result of our study is the demonstration of a correlation between P-gp expression and patients with HER2-positive breast tumors that do not express steroid receptors.
|
29181060 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
|
29637742 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
|
19807929 |
2009 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
|
24886669 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Subsequently, there is a significant decrease in both MDR1 and Bcl-x(L) gene expression and an enhancement in caspase-3 activity and chemosensitivity in the breast tumor cells.
|
19047049 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The quantitative real-time polymerase chain reaction (Q-RT-PCR) technique was used to assess the MDR1 and MMP2 RNA expression levels in primary breast tumor and lymph nodal specimens.
|
23280016 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analyses of human breast tumor specimens revealed a strong correlation between expression of Cox-2 and MDR1/Pgp170.
|
11501838 |
2001 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry confirmed that breast carcinoma cells lacked P-glycoprotein expression; however, interstitial mononuclear cells, morphologically consistent with lymphocytes or macrophages did show immunostaining in some of these breast tumors.
|
10092063 |
1999 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MDR1/gp170 expression has been studied in breast cancer, but the prevalence of this expression and its role in breast tumor drug resistance are unclear.
|
9214671 |
1997 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
P-Glycoprotein RNA expression was positive in eight of 23 lymphomas and two of 12 colon tumors; however, many other normal and malignant tissues, including lung, bladder, and breast tumors, had low or undetectable levels of P-glycoprotein RNA expression.
|
2466554 |
1989 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, transcripts derived from the MDR1 USP were detected in some drug-resistant cell lines and a high proportion of primary breast tumors (71.6%; n = 61), whereas they were present at low frequency in normal breast tissue (10%; n = 10).
|
15102684 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of MDR in breast tumors is related to their origination from a tissue that constitutively expresses Pgp as well as to the development of resistance during successive courses of chemotherapy.
|
7881104 |
1994 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The regulatory effect of Gal-1 on multidrug resistance (MDR) breast cancer cells is still unclear. qRT-PCR and western blot showed that Gal-1 and MDR gene 1 (MDR1) were both highly expressed in breast tumor tissues and cell lines.
|
28212576 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.
|
22311042 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
16773437 |
2006 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.
|
12684679 |
2003 |